Association between mRNA expression of chemotherapy-related genes and clinicopathological features in colorectal cancer: A large-scale population analysis

YUJI SHIMAMOTO1, MAMORU NUKATSUKA2, TEIJI TAKECHI1 and MASAKAZU FUKUSHIMA3

1Translational Research Laboratory, Taiho Pharmaceutical Co., Ltd., Uchikanda, Chiyoda-ku, Tokyo 101-0047; 2Translational Research Laboratory, Taiho Pharmaceutical Co., Ltd., Kawauchi-Chō, Tokushima-shi, Tokushima 771-0194; 3The Japan-Multinational Trial Organization, Naka-ku, Nagoya-shi, Aichi 460-0002, Japan

Received July 22, 2015; Accepted November 24, 2015

DOI: 10.3892/ijmm.2015.2427

Abstract. To establish the individualized treatment of patients with colorectal cancer, factors associated with chemotherapeutic effects should be identified. However, to the best of our knowledge, few studies are available on this topic, although it is known that the prognosis of patients and sensitivity to chemotherapy depend on the location of the tumor and that the tumor location is important for individualized treatment. In this study, primary tumors obtained from 1,129 patients with colorectal cancer were used to measure the mRNA expression levels of the following genes associated with the effects of standard chemotherapy for colorectal cancer: 5-fluorouracil (5-FU)-related thymidylate synthase (TYMS), dihydropterdine reductase (DPYD), folate-related dihydrofolate reductase (DHFR), folypolyglutamate synthase (FPGS) and gamma-glutamyl hydrolase (GGH); irinotecan-related topoisomerase I (TOP1); oxaliplatin-related excision repair cross-complementing 1 (ERCC1); biologic agent-related vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR). Large-scale population analysis was performed to determine the association of gene expression with the clinicopathological features, in particular, the location of the colorectal cancer. From the results of our analysis of the mRNA expression of these 10 genes, we noted the strongest correlation between DPYD and TYMP, followed by TYMS and DHFR. The location of the colorectal cancer was classified into 4 regions (the right- and left-sided colon, rectosigmoid and rectum) and was compared with gene expression. A significant difference in all genes, apart from VEGF, was noted. Of the remaining 9 genes, the highest expression of TYMS and DPYD was observed in the right-sided colon; the highest expression of GGH and EGFR was noted in the left-sided colon; the highest expression of DHFR, FPGS, TOP1 and ERCC1 was noted in the rectosigmoid, whereas TYMP expression was approximately equivalent in the right-sided colon and rectum, and higher than that in other locations. The data generated from this study may prove to be useful for the development of individualized chemotherapeutic treatments for patients with colorectal cancer, and will mean that the tumor location is taken into account.

Introduction

In 2012, colorectal cancer was estimated to be the third most common type of cancer after lung and prostate cancer in men, and the second most common after breast cancer in women worldwide. In terms of the mortality rate, it ranked fourth, after cancer of the lungs, liver and stomach in both men and women (1). Although colorectal cancer is principally treated by surgery, chemotherapy and radiotherapy may be given priority, depending on the stage of the disease. For many years, 5-fluorouracil (5-FU) alone or 5-FU and leucovorin were effectively used as chemotherapeutic agents for the treatment of colorectal cancer. However, the survival benefit in patients with metastatic colorectal cancer has been reported to be markedly increased by the combined use of chemotherapeutic agents, such as irinotecan and oxaliplatin with biological agents, such as bevacizumab for anti-vascular endothelial growth factor (VEGF) antibody therapy and cetuximab for anti-epidermal growth factor receptor (EGFR) antibody therapy, in addition to cytotoxic agents (2).

To increase the effectiveness of chemotherapy for patients with colorectal cancer, it is necessary to establish individualized treatment strategies and, therefore, identifying factors associated with the effects of chemotherapy for colorectal cancer also becomes important. Thymidylate synthase (TYMS), a 5-FU target, requires 5,10-methylenetetrahydrofolate (5,10-methylene-THF), a folate co-factor, as a methyl group donor.
and methylates deoxyuridine monophosphate (dUMP) to become deoxothymidine monophosphate (dTMP). It acts as a rate-limiting enzyme during DNA synthesis (3). As an active metabolite of 5-FU, 5-fluoro-dUMP (FdUMP) covalently links with TYMS and 5,10-methylene-THF, forming a ternary complex and inhibiting the TYMS response (3). Dihydroyirimidine dehydrogenase (DPYD) is a rate-limiting enzyme catalyzing the response during the first step of the catabolism of 5-FU (4). Thymidine phosphorylase (TYMP), which is associated with the metabolism of 5-FU, is an enzyme catalyzing the reversible phosphorylation of 5-FU to 5-fluoro-2'-deoxyuridine. TYMP is identical to platelet-derived endothelial-cell growth factor and is thought to be involved in angiogenesis (5). Salonga et al (6) and Soong et al (7) reported that the mRNA or protein expression of TYMS, DPYD and TYMP was associated with the antitumor effects of 5-FU. Leucovorin is metabolized in vivo into 5,10-methylene-THF, strengthens the ternary complex of FdUMP, TYMS and 5,10-methylene-THF, and strengthens the antitumor effects of 5-FU (8). Dihydrofolate reductase (DHFR) catalyzes the conversion of dihydrofolate into tetrahydrofolate, which is an important step in the generation of 5,10-methylene-THF (3). In addition, folate is converted from the monoglutamate to the polyglutamate form by folypolyglutamate synthase (FPGS) and can therefore be easily maintained within the cells, while the polyglutamate chain is cleaved by gamma-glutamyl hydro-lase (GGH) and is converted into the monoglutamate form. It is thought that the catalyzing of opposite reactions by FPGS and GGH in folate metabolism is associated with the adjustment of folate levels in cells, as well as with the augmentation of the effects of 5-FU by leucovorin (9). Topoisomerase I (TOP1), a target enzyme of irinotecan, destroys the superhelicity observed in DNA during DNA metabolic processes, such as replication and transcription; consequently, TOP1 plays a role in the regulation of DNA topology (10). The association of excision repair cross-complementing 1 (ERCC1), reportedly associated with the effects of oxaliplatin, is an excision nuclease involved in the nucleotide excision repair of DNA and plays an important role in the repair of platinum-induced DNA adducts (11,12). Both TOP1 and ERCC1 maintain the normal structure of DNA and are important for DNA functionality. VEGF is a key mediator in angiogenesis, consisting of multiple steps, and its high-level expression is thought to be closely associated with tumor growth and metastasis (13). EGFR plays an important role in the signaling pathway of epithelial cell growth, and its activation is thought to be closely associated with tumor invasion, metastasis and angiogenesis (14). Both VEGF and EGFR play important roles in signaling pathways associated with cell growth, such as angiogenesis and proliferation.

It is well known that not only embryological, morphological, physiological and molecular features, but also the prognosis of patients and their sensitivity to chemotherapy depend on whether the primary lesion of colorectal cancer is located on the right or left side (15-18). Consequently, the location of the colorectal cancer is thought to be important for deciding individualized treatment for patients with colorectal cancer. However, to the best of our knowledge, to date, there are few studies available on the association between the location of the colorectal cancer and the level of expression of genes related to the effects of chemotherapy for colorectal cancer.

Previously, we performed large-scale population studies investigating TYMS and DPYD activity, as well as protein and mRNA expression in various types of solid tumors and reported basic data regarding the comparisons of assays and the level of expression, according to the carcinoma (19,20). In this study, primary tumors obtained from 1,129 patients with colorectal cancer who received no chemotherapy were used. After measuring the genes related to standard chemotherapy for colorectal cancer (TYMS, DPYD, TYMP, DHFR, FPGS, GGH, TOP1, ERCC1, VEGF and EGFR), a large-scale population analysis was performed for the purpose of determining the association with clinicopathological features, and in particular, the location of the colorectal cancer.

Patients and methods

Patients and samples. Between January 2008 and June 2012, we collected samples from primary tumor surgeries conducted on 2,017 patients with colorectal cancer in 39 hospitals across Japan. All the hospitals participated in this study after approval was obtained from the ethical review board of each hospital. Formalin-fixed paraffin-embedded (FFPE) tumor specimens were used for the measurement of mRNA expression. The primary lesions of 1,129 patients with colorectal cancer who did not receive any chemotherapy were analyzed for the mRNA expression of 10 target genes (TYMS, DPYD, TYMP, DHFR, FPGS, GGH, TOP1, ERCC1, VEGF and EGFR). Of these, 888 patients were not included in the analysis: 80 patients (4.0%) who received pre-operative chemotherapy; 6 patients (0.3%) who were diagnosed with non-colorectal cancer based on a final pathological examination; 630 patients (31.2%) for whom some of the 10 target genes were not analyzed, at the hospitals’ request; 62 patients (3.1%) for whom none of the 10 target genes were analyzable due to an inadequate number of cancer cells in the FFPE tumor specimens; 110 patients (5.5%) for whom one or more targeted genes were not analyzable due to insufficient tumor volume or considerable variability in the measured values. In addition, not detectable (n.d.) results were included in the analyzed data. The clinicopathological features of the patients were investigated based on the Japanese classification of colorectal cancer: General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus, 7th edition (21).

Analysis of mRNA expression. The analysis of mRNA expression was performed as previously described (20). Briefly, the tumor sections (10-µm-thick) were stained with neutral fast red to enable histological visualization during laser-capture microdissection (PALM Robot-microbeam system; P.A.L.M. Microlaser Technologies AG, Munich, Germany), which was performed to ensure that only the tumor cells were collected. RNA was isolated from the FFPE tumor specimens using a novel proprietary procedure (Response Genetics, Los Angeles, CA, USA; United States Patent No. 6,248,535) and cDNA was obtained as previously described (22). The target cDNA sequences were amplified using quantitative polymerase chain reaction (qPCR) and a fluorescence-based real-time detection method [ABI PRISM 7900 Sequence Detection System (TaqMan); Applied Biosystems, Foster City, CA, USA] as previously described (23-25). The qPCR reaction mixture
Table I. Clinicopathological features of the 1,129 patients.

| Clinicopathological features                                      | No. of patients | %   |
|------------------------------------------------------------------|-----------------|-----|
| Age (mean, 66 years; median, 67 years; range, 24-94 years)       |                 |     |
| <67                                                             | 525             | 46.5|
| ≥67                                                             | 558             | 49.4|
| No available data                                               | 46              | 4.1 |
| Gender                                                           |                 |     |
| Male                                                             | 662             | 58.6|
| Female                                                           | 459             | 40.7|
| No available data                                               | 8               | 0.7 |
| Tumor location                                                   |                 |     |
| Right-sided colon (C, A, T)                                     | 324             | 28.7|
| Left-sided colon (D, S)                                         | 317             | 28.1|
| Rectosigmoid                                                    | 117             | 10.4|
| Rectum                                                          | 358             | 31.7|
| Proctos                                                          | 4               | 0.4 |
| No available data                                               | 9               | 0.8 |
| Histology                                                       |                 |     |
| Well/moderately differentiated                                   | 1004            | 88.9|
| Poorly differentiated                                            | 35              | 3.1 |
| Mucinos                                                          | 32              | 2.8 |
| Others                                                           | 16              | 1.4 |
| No available data                                               | 42              | 3.7 |
| Lymphatic invasion                                              |                 |     |
| ly0                                                             | 292             | 25.9|
| ly1, ly2, ly3                                                    | 746             | 66.1|
| No available data                                               | 91              | 8.1 |
| Venous invasion                                                 |                 |     |
| v0                                                              | 364             | 32.2|
| v1, v2, v3                                                       | 670             | 59.3|
| No available data                                               | 95              | 8.4 |
| Depth of tumor invasion                                          |                 |     |
| M, SM, MP                                                       | 197             | 17.4|
| SS, SE, SI, A, AI                                               | 901             | 79.8|
| No available data                                               | 31              | 2.7 |
| Lymph node metastasis                                           |                 |     |
| N0                                                              | 467             | 41.4|
| N1, N2, N3                                                      | 633             | 56.1|
| No available data                                               | 29              | 2.6 |
| Stage                                                            |                 |     |
| 0                                                               | 9               | 0.8 |
| I                                                               | 106             | 9.4 |
| II                                                              | 278             | 24.6|
| III                                                             | 482             | 42.7|
| IV                                                              | 191             | 16.9|
| No available data                                               | 63              | 5.6 |

Based on the General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus (Japanese Society for Cancer of the Colon and Rectum, 7th edition) (21). Tumor location: C, cecum; A, ascending colon; T, transverse colon; D, descending colon; S, sigmoid colon. Depth of tumor invasion: M, tumor invasion of mucosa; SM, tumor invasion of submucosa; MP, tumor invasion of muscularis propria; SS, tumor invasion of subserosa; SE, tumor invasion of serosa, SI, direct tumor invasion of other organs or structure in the intestine with serosa; AI, tumor invasion through muscularis propria into non-peritonealized, pericolic, or perirectal tissues; A, tumor invasion of other organs or structure in the intestine without serosa.

The mRNA expression was analyzed as a variable which was converted by using the natural logarithm and producing a normal distribution. Pearson's pairwise correlation coefficient was used to calculate the correlation of intergenic mRNA expression. For hierarchical cluster analysis of mRNA expression, the data were standardized using the means and standard deviation, while Ward's method was used to calculate the distance between clusters. For the equality of means, Welch's t-test or one-way analysis of variance (ANOVA) was performed. The analysis of the contingency table was performed using Fisher's exact test or χ² test. JMP version 9.0.2 (SAS Institute Japan Co., Ltd., Japan) was used for analysis, and a p-value <0.05 (two-tailed) was considered to indicate a statistically significant difference. The multiplicity of the test was not considered, as the analysis of this study was exploratory.

Results

Patient characteristics. The clinicopathological features of the 1,129 patients are presented in Table I. With regard to tumor location, the percentages obtained were similar for the right- and left-sided colon, and the rectum showed a slightly higher percentage. With regard to the depth of tumor invasion, tumor invasion of mucosa (M), tumor invasion of submucosa (SM) and tumor invasion of muscularis propria (MP) were equivalent to ≤T2 (Tis, T1 and T2) according to the TNM classification, 7th edition, developed by the Union for International Cancer Control (UICC), and accounted for a low percentage of 17.4% of the total. Tumor invasion of subserosa (SS), tumor invasion of serosa (SE), direct tumor invasion of other organs or structure in the intestine with serosa (SI), tumor invasion through muscularis propria into non-peritonealized, pericolic, or perirectal tissues (A), tumor invasion of other organs or structure in the intestine without serosa (AI) were equivalent to ≥T3 (T3a and T4b) according to the TNM classification and accounted for 79.8%. In addition, non-lymph node metastasis (N0) and lymph node metastases (≥N1) were 41.4 and 56.1%, respectively; stage I/II and stage III/IV disease were 34.0 and 59.6%, respectively, which indicated that the percentage of stage I/II disease tended to be lower.

Intergenic correlation and hierarchical cluster analysis. A summary of the results of the mRNA expression of the 10 target genes is presented in Table II, and the intergenic correlations obtained are listed in Table III. For the patients whose mRNA expression was not detectable (n.d.), the minimum mRNA expression of that gene was inserted as an alternative. The frequency of n.d. was as follows: TYMS, 1 (0.1%); DPYD, 60˚C for 10 min, followed by 42 cycles at 95˚C for 15 sec and 60˚C for 1 min. The mRNA expression levels were expressed as values relative to those of β-actin (ACTB), which was used as the internal reference. If the threshold cycle value for a gene of interest was ≥39.0, the expression for that gene was considered to be not detectable (n.d.), but in the case of ACTB it was measured normally.

Statistical analysis. mRNA expression was analyzed as a variable which was converted by using the natural logarithm and producing a normal distribution. Pearson's pairwise correlation coefficient was used to calculate the correlation of intergenic mRNA expression. For hierarchical cluster analysis of mRNA expression, the data were standardized using the means and standard deviation, while Ward's method was used to calculate the distance between clusters. For the equality of means, Welch's t-test or one-way analysis of variance (ANOVA) was performed. The analysis of the contingency table was performed using Fisher's exact test or χ² test. JMP version 9.0.2 (SAS Institute Japan Co., Ltd., Japan) was used for analysis, and a p-value <0.05 (two-tailed) was considered to indicate a statistically significant difference. The multiplicity of the test was not considered, as the analysis of this study was exploratory.
Table II. Summary of the mRNA expression levels of the 10 genes analyzed in this study in the 1,129 patients.

| Gene   | Median | Min  | Max  | Mean | SD  |
|--------|--------|------|------|------|-----|
| TYMS   | 3.86   | 0.40 | 64.20| 1.34 | 0.66|
| DPYD   | 0.28   | 0.03 | 4.61 | -1.30| 0.85|
| TYMP   | 2.72   | 0.22 | 45.30| 1.02 | 0.79|
| DHFR   | 4.33   | 0.40 | 27.46| 1.43 | 0.63|
| FPGS   | 0.59   | 0.15 | 4.49 | -0.53| 0.49|
| GGH    | 12.71  | 0.26 | 166.47| 2.45 | 1.09|
| TOP1   | 2.79   | 0.41 | 107.07| 1.02 | 0.52|
| ERCCI  | 1.67   | 0.27 | 18.06| 0.52 | 0.55|
| VEGF   | 7.39   | 0.93 | 73.19| 1.99 | 0.65|
| EGFR   | 1.35   | 0.11 | 55.07| 0.29 | 0.61|

Table III. Correlations of the mRNA expression of the 10 log-transformed genes.

| Gene | TYMS | DPYD | TYMP | DHFR | FPGS | GGH | TOP1 | ERCCI | VEGF | EGFR |
|------|------|------|------|------|------|-----|------|-------|------|------|
| TYMS | 1    | 0.596|      |      |      |     |      |       |      |      |
| DPYD |      | 1    | 0.629|      |      |     |      |       |      |      |
| TYMP | 0.596| 0.629| 1    |      |      |     |      |       |      |      |
| DHFR | 0.596|      | 1    | 0.438| 0.387|     |      | 0.373 |      |      |
| FPGS |      |      |      | 1    | 0.456|     |      |       |      |      |
| GGH  | 0.438|      |      |      | 1    |     |      | 0.341 |      |      |
| TOP1 | 0.387|      |      |      |      | 1   |      |       |      |      |
| ERCCI| 0.427|      |      |      |      |     | 1    |       |      |      |
| VEGF | 0.373|      |      |      |      |     |      | 0.341 | 1    |      |
| EGFR | 0.456|      |      |      |      |     |      |      |      | 1    |

Only Pearson’s correlations >0.3 are shown (p<0.0001).

Association of mRNA expression and clinicopathological features. The association between the mRNA expression of 10 target genes and the clinicopathological features is presented in Table VI. In relation to the location of the tumor, a significant difference was noted in all genes apart from VEGF when 4 locations were compared (the right- and left-sided colon, rectosigmoid and rectum), with the exception of the rectum; only 4 patients had a tumor at this location. Specifically, TYMS and DPYD showed the highest level of expression in the right-sided colon; GGH and ERCC1 showed the highest level of expression in the left-sided colon; DHFR, FPGS, TOP1 and ERCCI showed the highest level of expression in the rectosigmoid; TYMP showed approximately equivalent expression in the right-sided colon and rectum, where the expression was higher than in the other locations. On comparing two locations (right- and left-sided colon cancer) in patients with colon cancer only, a significantly high level of expression was noted in right-sided colon cancer for TYMS (fold change, 1.22; p=0.0001), DPYD (1.27-fold; p=0.001), TYMP (1.31-fold; p<0.0001), and FPGS (1.09-fold; p=0.020). By contrast, a significantly high level of expression was observed in left-sided colon cancer for GGH (1.74-fold; p=0.0001), TOP1 (1.17-fold; p<0.0001) and ERCC1 (1.15-fold; p=0.006) genes, and no significant difference was noted for DHFR (1.06-fold; p=0.226), ERCCI (1.08-fold; p=0.084) and VEGF (1.07-fold; p=0.191) (data not shown). For histology, there was a significant difference in 7 genes, excluding DHFR, VEGF and EGFR. For TYMS, DPYD and TYMP, the highest levels of expression were observed in patients with poorly differentiated adenocarcinoma, while the lowest levels of expression were observed in patients with well/moderately differentiated adenocarcinoma. For FPGS, GGH, TOP1 and ERCCI, the lowest levels of expression were observed in patients with mucinous adenocarcinoma; for FPGS and ERCCI, the highest level of expression was observed in patients with poorly differentiated adenocarcinoma; and for GGH and TOP1, the highest level of expression was observed in patients with well/moderately differentiated adenocarcinoma. As regards the depth of tumor invasion, a significantly higher
level of expression was found in T1/2 as compared to T3/4 for TYMS, TYMP, DHFR, and ERCC1, while higher expression was found in T3/4 for VEGF only. For lymph node metastasis, there was a significant difference in TYMS, DHFR and ERCC1; a significantly higher level of expression was found in N0 than N≥1. For stage, there was a significant difference in TYMS, TYMP, DHFR and ERCC1, whereas a significantly higher level of expression was found in stage I/II than stage III/IV disease.

Comparison of clinicopathological features in right- or left-sided colon cancer. A comparison of the clinicopathological features between the patients with right- and left-sided colon cancer is presented in Table VII. A significant difference was found with respect to age, histology, lymph node metastasis and stage. The frequencies of elderly individuals, poorly differentiated and mucinous adenocarcinomas, N0 and stage I/II disease tended to be higher in right-sided colon cancer than left-sided colon cancer. The frequency of female patients tended to be higher for right- than left-sided colon cancer although the difference was not significant.

Discussion

In this study, FFPE tumor specimens of primary tumors obtained from 1,129 patients with colorectal cancer were used. We measured mRNA expression levels of 10 genes associated with the effects of standard chemotherapy for colorectal cancer (TYMS, DPYD, TYMP, DHFR, FPGS, GGH, TOP1, ERCC1, VEGF and EGFR), and determined their association with clinicopathological features, in particular, the location of colorectal cancer.

Table V. Comparison of clinicopathological features in two clusters of gene expression.

| Clinicopathological features | No. of patients | p-value |
|-----------------------------|-----------------|---------|
| Age (years)                 |                 |         |
| <67                         | 252             | 273     | 0.394 |
| ≥67                         | 253             | 305     |       |
| Gender                      |                 |         |
| Male                        | 312             | 350     | 0.761 |
| Female                      | 221             | 238     |       |
| Tumor location              |                 |         |
| Right-sided colon           | 150             | 174     | 0.305 |
| Left-sided colon            | 156             | 161     |       |
| Rectosigmoid                | 47              | 70      |       |
| Rectum                      | 177             | 181     |       |
| Histology                   |                 |         |
| Well/moderately differentiated | 479           | 525     | 0.008 |
| Poorly differentiated        | 15              | 20      |       |
| Mucinous                    | 24              | 8       |       |
| Venous invasion             |                 |         |
| ly0                         | 129             | 163     | 0.039 |
| ly1, ly2, ly3               | 383             | 363     |       |
| Venous invasion             |                 |         |
| v0                          | 171             | 193     | 0.241 |
| v1, v2, v3                  | 341             | 329     |       |
| Depth of tumor invasion     |                 |         |
| T1, T2                      | 102             | 95      | 0.238 |
| T3, T4                      | 424             | 477     |       |
| Lymph node metastasis       |                 |         |
| N0                          | 202             | 265     | 0.006 |
| N1, N2, N3                  | 327             | 306     |       |
| Stage                       |                 |         |
| I, II                       | 166             | 218     | 0.013 |
| III, IV                     | 345             | 328     |       |

p-values were calculated by Fisher's exact test or χ² test.
### Table VI. Associations between log-transformed mRNA expression levels and clinicopathological features.

| Clinicopathological features | TYMS | DPDY | DHFR | TYMP | TOP1 | ERCC1 | VEGF | EGFR |
|-----------------------------|------|------|------|------|------|-------|------|------|
| **Log-transformed mRNA expression levels (mean ± SD)** |      |      |      |      |      |       |      |      |
| Age (years) |       |      |      |      |      |       |      |      |
| <67 | 1.34±0.63 | 1.33±0.84 | 1.03±0.75 | 1.26±0.63 | 1.42±0.63 | 2.52±1.04 | 1.04±0.51 | 0.5±0.59 |
| ≥67 | 1.39±0.67 | 1.01±0.82 | 1.34±0.62 | 1.7±1.13 | 1.7±1.13 | 2.53±1.13 | 1.34±0.62 | 0.25±0.62 |
| p-value | 0.024 | 0.084 | 0.045 | 0.046 | 0.047 | 0.045 | 0.046 | 0.047 |
| Gender |       |      |      |      |      |       |      |      |
| Male | 1.34±0.65 | 1.34±0.68 | 1.34±0.68 | 1.34±0.68 | 1.34±0.68 | 1.34±0.68 | 1.34±0.68 | 1.34±0.68 |
| Female | 1.34±0.65 | 1.34±0.68 | 1.34±0.68 | 1.34±0.68 | 1.34±0.68 | 1.34±0.68 | 1.34±0.68 | 1.34±0.68 |
| p-value | 0.973 | 0.945 | 0.973 | 0.945 | 0.973 | 0.945 | 0.973 | 0.945 |
| Tumor location |       |      |      |      |      |       |      |      |
| Right-sided colon | 1.45±0.66 | 1.45±0.66 | 1.45±0.66 | 1.45±0.66 | 1.45±0.66 | 1.45±0.66 | 1.45±0.66 | 1.45±0.66 |
| Left-sided colon | 1.25±0.66 | 1.25±0.66 | 1.25±0.66 | 1.25±0.66 | 1.25±0.66 | 1.25±0.66 | 1.25±0.66 | 1.25±0.66 |
| Rectosigmoid | 1.25±0.66 | 1.25±0.66 | 1.25±0.66 | 1.25±0.66 | 1.25±0.66 | 1.25±0.66 | 1.25±0.66 | 1.25±0.66 |
| Rectum | 1.39±0.71 | 1.34±0.71 | 1.34±0.71 | 1.34±0.71 | 1.34±0.71 | 1.34±0.71 | 1.34±0.71 | 1.34±0.71 |
| p-value | 0.002 | 0.004 | 0.002 | 0.004 | 0.002 | 0.004 | 0.002 | 0.004 |
| Histology |       |      |      |      |      |       |      |      |
| Well/moderately differentiated | 1.82±0.68 | 1.82±0.68 | 1.82±0.68 | 1.82±0.68 | 1.82±0.68 | 1.82±0.68 | 1.82±0.68 | 1.82±0.68 |
| Poorly differentiated | 1.84±0.68 | 1.84±0.68 | 1.84±0.68 | 1.84±0.68 | 1.84±0.68 | 1.84±0.68 | 1.84±0.68 | 1.84±0.68 |
| Mucinous | 1.84±0.68 | 1.84±0.68 | 1.84±0.68 | 1.84±0.68 | 1.84±0.68 | 1.84±0.68 | 1.84±0.68 | 1.84±0.68 |
| p-value | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 |
| Lymphatic invasion |       |      |      |      |      |       |      |      |
| 0 | 1.42±0.66 | 1.42±0.66 | 1.42±0.66 | 1.42±0.66 | 1.42±0.66 | 1.42±0.66 | 1.42±0.66 | 1.42±0.66 |
| 1, 2, 3 | 1.42±0.66 | 1.42±0.66 | 1.42±0.66 | 1.42±0.66 | 1.42±0.66 | 1.42±0.66 | 1.42±0.66 | 1.42±0.66 |
| p-value | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 |
| Venous invasion |       |      |      |      |      |       |      |      |
| 0 | 1.42±0.66 | 1.42±0.66 | 1.42±0.66 | 1.42±0.66 | 1.42±0.66 | 1.42±0.66 | 1.42±0.66 | 1.42±0.66 |
| 1, 2, 3 | 1.42±0.66 | 1.42±0.66 | 1.42±0.66 | 1.42±0.66 | 1.42±0.66 | 1.42±0.66 | 1.42±0.66 | 1.42±0.66 |
| p-value | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 |
| Depth of tumor invasion |       |      |      |      |      |       |      |      |
| D1, D1, D1 | 1.46±0.61 | 1.46±0.61 | 1.46±0.61 | 1.46±0.61 | 1.46±0.61 | 1.46±0.61 | 1.46±0.61 | 1.46±0.61 |
| D1, D2, D3 | 1.46±0.61 | 1.46±0.61 | 1.46±0.61 | 1.46±0.61 | 1.46±0.61 | 1.46±0.61 | 1.46±0.61 | 1.46±0.61 |
| p-value | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 |
From the results of mRNA expression analysis of the 10 genes included in this study, the strongest correlation was noted between \textit{DPYD} and \textit{TYMP}. Several studies have reported a similar correlation between expression levels in colorectal cancer (26-33). \textit{DPYD} and \textit{TYMP} encode enzymes related to the metabolism of 5-FU, and it seems likely that the expression levels of these genes in colorectal cancer tissues are co-regulated. In addition, the results from this study indicate a weaker correlation between \textit{TYMS} and \textit{DHFR} than that between \textit{DPYD} and \textit{TYMP}. Uetake et al also reported a similar correlation in stage Ⅲ colon cancer (33). Considering that DHFR plays an important role in the generation of 5,10-methylene-THF as a co-factor of the TYMS response, it is plausible that the level of gene expression of both enzymes is correlated.

From the results of mRNA expression analysis of the 10 genes included in this study, the strongest correlation was noted between \textit{DPYD} and \textit{TYMP}. Several studies have reported a similar correlation between expression levels in colorectal cancer (26-33). \textit{DPYD} and \textit{TYMP} encode enzymes related to the metabolism of 5-FU, and it seems likely that the expression levels of these genes in colorectal cancer tissues are co-regulated. In addition, the results from this study indicate a weaker correlation between \textit{TYMS} and \textit{DHFR} than that between \textit{DPYD} and \textit{TYMP}. Uetake et al also reported a similar correlation in stage Ⅲ colon cancer (33). Considering that DHFR plays an important role in the generation of 5,10-methylene-THF as a co-factor of the TYMS response, it is plausible that the level of gene expression of both enzymes is correlated.

It has previously been reported that colorectal cancer, particularly colon cancer, exhibits embryologic, morphologic, physiologic and molecular differences between the right and left sides, which leads to differences in the prognosis of
patients and their sensitivity to chemotherapy (15-18). In relation to the clinicopathological features, in these studies, it has been posited that the numbers of elderly individuals, women, mucinous adenocarcinoma, high grade (poorly differentiated/undifferentiated) and negative lymph node metastasis is higher in right-than left-sided colon cancer. In our study, similar, reproducible results were noted. As regards the molecular features, a microsatellite instability phenotype (MSI\textsuperscript{+}) and CpG island methylator phenotype (CIMP\textsuperscript{+}) are common in right-sided colon cancer, whereas chromosomal instability is common in left-sided colon cancer (15-18). Kawakami et al (34) analyzed the association between the CIMP\textsuperscript{+} status and the expression level of gene-related folate and nucleotide metabolism in the primary tumors of 114 patients from Australia with colorectal cancer. They reported that the low-level expression of GG\textsubscript{H} and high-level expression of TYMP were very strongly associated with CIMP\textsuperscript{+} and CIMP\textsuperscript{-} related clinicopathological and molecular features. They also reported that a significantly higher level of TYMP expression and a significantly lower level of GG\textsubscript{H} expression were found in right- as compared to left-sided colorectal cancer (34). Moreover, they pointed out the possibility that low-level GG\textsubscript{H} expression may lead to the maintenance of folate in the polyglutamate form in the cells, which is associated with DNA hypermethylation, and that 5-FU plus leucovorin therapy may then be more effective (34). In a study of 76 Japanese patients with stage II/III colorectal cancer, Sadahiro et al reported that a significantly high level of TYMP expression was found in cases of right rather than left-sided colorectal cancer and that preoperative uracil-tegafur (UFT) plus leucovorin therapy resulted in a significantly strong histological response (35). In the present study, in relation to right-sided colon cancer, we noted a significantly higher level of TYMP expression and a lower level GG\textsubscript{H} expression than in left-sided colon cancer. Considering these results, it may be worthwhile to determine the physiological significance of TYMP and GG\textsubscript{H} expression in patients with colorectal cancer in the future, in order to examine the hypothesis that 5-FU-based chemotherapy combined with leucovorin may be more effective in cases of right-sided colon cancer.

Ricciardiello et al reported that TYMS protein expression, as assessed by immunohistochemistry (IHC), did not differ significantly between right- and left-sided colorectal cancer, but a significantly high level of expression in MSI\textsuperscript{+} colorectal cancer was noted (36). Jensen et al also reported that the protein expression of TYMS (studied by IHC) was significantly high in MSI\textsuperscript{+} colorectal cancer (37). On the other hand, Sinicropo et al reported that there was no correlation between the MSI\textsuperscript{+} status and TYMS protein expression (as measured by IHC) (38). Thus, the association between TYMS protein expression and the MSI\textsuperscript{+} status remains controversial. In our study, as regards TYMS, its mRNA expression was found to be higher in right-sided colon cancer in which MSI\textsuperscript{+} was common, than in left-sided colon cancer. The analysis of the clinicopathological features of all the patients with colorectal cancer in this study revealed a high level of TYMS expression in the elderly, those with poorly differentiated adenocarcinoma and N0, which are common in right-sided colon cancer. However, as regards the association between TYMS expression and the location of colorectal cancer, further studies, which will include the association of TYMS with molecular features, such as the MSI\textsuperscript{+} status, are warranted in the future.

Recently, Missiaglia et al performed gene expression analysis of a colon cancer dataset on 914 patients who were registered in The Cancer Genome Atlas (TCGA) collection and Pan European Trial Adjuvant Colon Cancer (PETACC3) adjuvant chemotherapy trial. According to their study, the expression of EGFR and human epidermal growth factor receptor 2 (HER2) was advanced in left- rather than right-sided colon cancer, which activated EGFR signaling, and the usefulness of anti-EGFR agents was suggested (39). Similarly, the results of our study demonstrated that a significantly higher level of EGFR expression was noted in left- rather than right-sided colon cancer. Hence, it is necessary to perform research on individualized treatment which combines the location of colorectal cancer and EGFR expression levels with the mutation status of KRAS and BRAF, as well as EGFR inhibitors.

Loupakis et al analyzed three independent cohorts in order to examine the association between the primary tumor of metastatic colorectal cancer and the efficacy of first-line chemotherapy. They reported that patients with primary tumors on the left side of the colon achieved significantly superior overall survival than those with primary tumors on the right side (40). They also analyzed gene expression in an exploratory manner using the archival series of 181 independent primary tumor samples. They inferred that the mRNA expression of ERCC1 was significantly higher in right- rather than left-sided colorectal cancer, although the mRNA expression level of VEGF ligands A, B and C, as well as VEGF receptors 1 and 2 showed no difference between right- and left-sided colorectal cancer. This is, perhaps, one of the factors involved in chemoresistance in patients with right-sided colorectal cancer (40). In our study, although VEGF exhibited few differences in the level of expression according to the location of the tumor and the expression of ERCC1 was the lowest in the patients with left-sided colon cancer, the level of expression for ERCC1 was the highest in the rectosigmoid. Additionally, for ERCC1, there was no significant difference in the comparison between right- and left-sided colon cancer. Further research on the differences in sensitivity to oxaliplatin between patients with right- and left-sided colorectal cancer and the association with ERCC1 expression is warranted.

In our analysis of the association between gene expression and five factors related to the extent of cancer, namely lymphatic invasion, vein invasion, depth of tumor invasion, lymph node metastasis and stage, a significant difference was noted in all the five factors for TYMS, whereas DPYD, TYP, DHFR, FPGS, ERCC1 and VEGF showed a significant difference in 1-4 factors. Of these, with the exception that the VEGF gene showed a significantly higher level of expression in T3/4 than T1/2, high-level expression was found in the group at a less-advanced stage rather than the group in the more advanced stages of cancer. This tendency is consistent with the results of the hierarchical cluster analysis. However, a comparison of patient characteristics was made between the 1,129 Japanese patients with colorectal cancer in our study and the data from 30,002 patients who were registered with the Japanese Society for Cancer of the Colon and Rectum between 1993 and 1997 (41), as well as the data from 621 patients who were registered in a single institution in Japan between 1992 and 2002 (42). This
comparison revealed that, although age, gender, tumor location and histology had generally similar distributions, the percentages of T1/2, N0 and stage I/II were clearly low, and as a whole, the stage of cancer tended to be more advanced in our study. Consequently, it is likely necessary to consider the data on the association between gene expression levels in this study and the clinicopathological features associated with the progress of cancer with caution.

In this large-scale population study, we clarified the association between the mRNA expression of genes associated with the effects of standard chemotherapy for colorectal cancer and clinicopathological features, particularly the location of the colorectal cancer. It is hoped that the results of this study will become useful reference data for conducting research on individualized chemotherapy for colorectal cancer that takes into consideration the location of colorectal cancer.

Acknowledgements

The authors wish to thank all of the patients who participated in this study, and the clinicians at the hospitals named in the Appendix, who collaborated with us in measuring gene expression in the colorectal cancer specimens. In addition, we would like to thank Editage (www.editage.jp) for English language editing.

References

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136: E359-E386, 2015.
2. Meyerhardt J and Mayer RJ: Systemic therapy for colorectal cancer. N Engl J Med 352: 476-487, 2005.
3. Wilson PM, Danenberg PV, Johnston PG, Lenz HJ and Ladner RD: Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. Nat Rev Clin Oncol 11: 282-298, 2014.
4. van Kuijlenburg AB: Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer J 40: 939-950, 2004.
5. Toi M, Atiqur Rahman M, Bando H and Chow LW: Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment. Lancet Oncol 6: 159-166, 2005.
6. Salonga D, Danenberg KD, Johnson M, Metzger R, Groschen S, Tsao-Wei DD, Lenz HJ, Leinwand CG, Leinwand L, Diasio RB and Danenberg PV: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6: 1322-1327, 2000.
7. Soong R, Shah N, Salto-Tellez M, Tai BC, Soo RA, Han HC, Ng SS, Tan WL, Zeps N, Joseph D, et al: Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Ann Oncol 19: 915-919, 2008.
8. Laufman LR, Krzeczkowski KA, Roach R and Segal M: Leucovorin plus 5-fluorouracil: an effective treatment for metastatic colon cancer. J Clin Oncol 5: 1394-1400, 1987.
9. Sakamoto E, Tsukikasa O, Ogi S, Kobunai T, Tsujimoto H, Sakamoto K, Okayama Y, Sugimoto Y, Oka T, Fukushima M and Oka T: Folypholyglutamate synthase and gamma-glutamyl hydrolase regulate leucovorin-enhanced 5-fluorouracil anticancer activity. Biochem Biophys Res Commun 365: 801-807, 2008.
10. Pommier Y: Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 6: 789-802, 2006.
11. Shirou T, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, Groschen S, Tsao-Wei DD, Danenberg PV and Lenz HJ: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19: 4298-4304, 2001.
12. Bohanes P, Labonte MJ and Lenz HJ: A review of excision repair cross-complementation group I in colorectal cancer. Clin Colorectal Cancer 10: 157-164, 2011.
13. Rieckin DJ and Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011-1027, 2005.
14. Baselga J and Arteaga CL: Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23: 2445-2459, 2005.
15. Elsalih H, Joseph D, Grieu F, Zeps N, Spry N and Iacopetta B: Association of tumour size and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 355: 1745-1750, 2000.
16. Iacopetta B: Are there two sides to colorectal cancer? Int J Cancer 101: 403-408, 2002.
17. Gervaz P, Bucher P and Morel P: Two colonos-two cancers: paradigm shift and clinical implications. J Surg Oncol 88: 261-266, 2004.
18. Söreide K, Janssen EA, Siistland H, Körner H and Baak JP: Microsatellite instability in colorectal cancer. Br J Surg 93: 395-406, 2006.
19. Fukushima M, Morita M, Ikeda K and Nagayama S: Population study of expression of thymidylate synthase and dihydropyrimidine dehydrogenase in patients with solid tumors. Int J Mol Med 9: 839-844, 2003.
20. Fukui Y, Oka T, Nagayama S, Danenberg PV, Danenberg KD and Fukushima M: Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis. Int J Mol Med 22: 709-716, 2008.
21. General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus. Japanese Society for Cancer of the Colon and Rectum (eds). 7th edition, Kanehara & Co., Ltd., Kanehara, Tokyo, 2006.
22. Lord RV, Salonga D, Danenberg KD, Peters JH, DeMeester TR, Park JM, Johansson J, Skinner KA, Chandrasoma P, DeMeester SR, et al: Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg 4: 135-142, 2000.
23. Heid CA, Stevens J, Livak KJ and Williams PM: Real-time quantitative PCR. Genome Res 6: 986-994, 1996.
24. Gibson UE, Heid CA and Williams PM: A novel method for real time quantitative RT-PCR. Genome Res 6: 995-1001, 1996.
25. Kuramochi H, Hayashi K, Uchida K, Miyayama S, Shinmizu D, Vailböhmer D, Park S, Danenberg KD, Takasaki K and Danenberg PV: Vascular endothelial growth factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer. Clin Cancer Res 12: 29-33, 2006.
26. Ichikawa W, Uetake H, Shirota Y, Yamada H, Takahashi T, Nihei Z, Sugihara K, Sasaki Y and Hirayama R: Both gene expression for orotoposphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy in metastatic colorectal cancer. Br J Cancer 89: 1486-1492, 2003.
27. Yoshimare K, Kubota T, Watanabe M, Wada N, Nishibori H, Hasegawa H, Kitajima M, Takechi T and Fukushima M: Gene expression in colorectal cancer and in vitro chemosensitivity to 5-fluorouracil: a study of 88 surgical specimens. Cancer Sci 94: 633-638, 2003.
28. Inokuchi M, Uetake H, Shirota Y, Yamada H, Tajima M and Sugihara K: Gene expression of 5-fluorouracil metabolic enzymes in primary colorectal cancer and corresponding liver metastasis. Cancer Chemother Pharmacol 53: 391-396, 2004.
29. Uchida K, Danenberg KV, Danenberg KD and Grem JL: Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine. BMC Cancer 8: 306, 2008.
30. Sameshima S, Tomozawa S, Kojima M, Kокоtsu S, Motegi K, Horikoshi H, Okada K, Kon Y and Sawada T: 5-Fluorouracil-related gene expression in primary sites and hepatic metastases of colorectal carcinomas. Anticancer Res 28 (3A): 1477-1481, 2008.
31. Lormatomo K, Kuzwabara K, Tajima Y, Amano K, Hattori S, Ohsawa T, Okada N, Ishibashi K, Haga N and Ishida H: Thymidylate synthase and thymidine phosphorylase mRNA expression in primary cancers using laser capture microdissection is useful for prediction of the efficacy of FOLFOX treatment in colorectal cancer patients with liver metastasis. Oncol Lett 3: 983-989, 2012.
32. Goto T, Shinmura K, Yokomizo K, Sakuraba K, Kitamura Y, Shirahata A, Saito M, Kigawa G, Nemoto H, Sanada Y and Hibi K: Expression levels of thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase in patients with colorectal cancer. Anticancer Res 32: 1757-1762, 2012.

33. Uetake H, Ishikawa T, Matsu S and Sugihara K: Gene expression analysis as a biomarker study for ACTS-CC trial (TRICC0706), a phase III trial for adjuvant chemotherapy of S-1 and UFT/LV against stage III colon cancer in Japan. Cancer Res 72 (8 Suppl): 4516, 2012.

34. Kawakami K, Ooyama A, Ruszkiewicz A, Jin M, Watanabe G, Moore J, Oka T, Iacopetta B and Minamoto T: Low expression of gamma-glutamyl hydrolase mRNA in primary colorectal cancer with the CpG island methylator phenotype. Br J Cancer 98: 1555-1561, 2008.

35. Sadahiro S, Suzuki T, Tanaka A, Okada K, Nagase H and Uchida J: Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer. Cancer Chemother Pharmacol 70: 285-291, 2012.

36. Ricciardiello L, Ceccarelli C, Angiolini G, Pariali M, Chieco P, Paterini P, Biasco G, Martinelli GN, Roda E and Bazzoli F: High thymidylate synthase expression in colorectal cancer with microsatellite instability: Implications for chemotherapeutic strategies. Clin Cancer Res 11: 4234-4240, 2005.

37. Jensen SA, Vainer B, Kruhøffer M and Sørensen JB: Microsatellite instability in colorectal cancer and association with thymidylate synthase and dihydropyrimidine dehydrogenase expression. BMC Cancer 9: 25, 2009.

38. Sinicrope FA, Rego RL, Halling KC, Foster NR, Sargent DJ, LaPlant B, French AJ, Allegra CJ, Laurie JA, Goldberg RM, et al: Thymidylate synthase expression in colon carcinomas with microsatellite instability. J Clin Oncol 24: 2738-2744, 2006.

39. Missiaglia E, Jacobs B, D’Ario G, Di Narzo AF, Soneson C, Budimska E, Popovici V, Vecchione L, Gerster S, Yan P, et al: Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol 25: 1995-2001, 2014.

40. Loupakis F, Yang D, Yau L, Feng S, Cremolini C, Zhang W, Maus MK, Antoniotti C, Langer C, Scherer SJ, et al: Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst 107: dju427, 2015.

41. Kotake K, Honjo S, Sugihara K, Kato T, Kodaira S, Takahashi T, Yasutomi M, Muto T and Koyama Y: Changes in colorectal cancer during a 20-year period: an extended report from the multi-institutional registry of large bowel cancer, Japan. Dis Colon Rectum 46 (Suppl): S32-S43, 2003.

42. Sakamoto K, Machi J, Prygrocki M, Watanabe T, Hosoda S, Sugano M, Tomiki Y and Kamano T: Comparison of characteristics and survival of colorectal cancer between Japanese-Americans in Hawaii and native Japanese in Japan. Dis Colon Rectum 49: 50-57, 2006.

Appendix

Collaborating hospitals: Chiba University Hospital, Fujita Health University Hospital, Gifu University Hospital, Hachijo Digestive Disease Hospital, Hanga City Hospital, Himeji Medical Center, Hyogo Prefectural Kagawa Medical Center, JCHO Kobe Central Hospital, Kanto Rosai Hospital, Keio University Hospital, Kinki University Hospital, Kitano Hospital, Kobe City Medical Center General Hospital, Kobe City Medical Center West Hospital, Kohsei Chuo General Hospital, Nagoya University Hospital, National Center for Global Health and Medicine Center Hospital, Nihon University Itabashi Hospital, Niitsu Medical Center Hospital, Omori Red Cross Hospital, Osaka Rosai Hospital, Osaka University Hospital, Saitama Medical Center, Sakai City Hospital, Sendai Red Cross Hospital, Showa University Fujigaoka Hospital, Showa University Hospital, The Jikei University Hospital, Tohoku Rosai Hospital, Tohoku University Hospital, Toho University Omori Medical Center, Tokushima Red Cross Hospital, Tokyo Medical University Hachioji Medical Center, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo Metropolitan Tama Medical Center, Totoku Kyoritsu Second Hospital, Toyohashi Municipal Hospital, University of Yamanashi Hospital, Yamaguchi University Hospital.